Generic placeholder image

Recent Patents on Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-891X
ISSN (Online): 2212-4071

Novel Compounds and Drugs and Recent Patents in Treating Multidrug- Resistant and Extensively Drug-Resistant Tuberculosis

Author(s): Attapon Cheepsattayakorn and Ruangrong Cheepsattayakorn

Volume 7 , Issue 2 , 2012

Page: [141 - 156] Pages: 16

DOI: 10.2174/157489112801619683

Price: $65

Abstract

A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.

Keywords: Multidrug, extensively-drug, resistant, tuberculosis, compounds, novel, patents


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy